In the past few years, CD90 has been considered as a human GBM stem cell (GSC) marker (Liu et al., 2006; Kang and Kang, 2007; Tomuleasa et al., 2010; He et al., 2012; Nitta et al., 2015). This evidence concerns the gene THY1 and glioblastoma.